NBIX Form 4: Director trades 15,000 Neurocrine shares via 10b5-1

Rhea-AI Filing Summary

Neurocrine Biosciences (NBIX) reported an insider equity transaction by a director. On 11/25/2025, the reporting person exercised a non-qualified stock option for 15,000 shares of common stock at an exercise price of $47.89 per share and acquired those shares.

On the same date, the director disposed of 15,000 shares of common stock in an open-market sale coded "S," at a weighted average price of $143.3675 per share, executed under a Rule 10b5-1 trading plan adopted on August 26, 2025. After these transactions, the reporting person directly beneficially owned 7,068 shares of Neurocrine common stock.

Insider Trade Summary

Net Seller: 15,000 shares ($2,150,513)

Net Sell 3 txns

Insider MORROW GEORGE J

Role Director

Sold 15,000 shs ($2.15M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option	15,000	$0.00	--
Exercise	Common Stock	15,000	$47.89	$718K
Sale	Common Stock	15,000	$143.3675	$2.15M

Holdings After Transaction: Non-Qualified Stock Option — 0 shares (Direct); Common Stock — 22,068 shares (Direct)

Footnotes (1)

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.51 to $144.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORROW GEORGE J

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		M		15,000	A	$47.89	22,068	D
Common Stock	11/25/2025		S(1)		15,000	D	$143.3675(2)	7,068	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$47.89	11/25/2025		M			15,000	(3)	05/20/2026	Common Stock	15,000	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.51 to $144.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options were due to expire on May 20, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neurocrine Biosciences (NBIX) report on this Form 4?

The filing reports that a director of Neurocrine Biosciences exercised 15,000 non-qualified stock options and sold 15,000 shares of NBIX common stock on 11/25/2025.

How many Neurocrine Biosciences (NBIX) shares were sold and at what price?

The director sold 15,000 shares of NBIX common stock at a weighted average price of $143.3675 per share, with individual trades ranging from $141.51 to $144.57.

What was the exercise price of the Neurocrine Biosciences (NBIX) stock options?

The non-qualified stock option was exercised at a price of $47.89 per share for 15,000 underlying shares of NBIX common stock.

How many Neurocrine Biosciences (NBIX) shares does the insider own after the transaction?

Following the reported transactions, the director beneficially owned 7,068 shares of Neurocrine Biosciences common stock in direct ownership form.

Was the Neurocrine Biosciences (NBIX) stock sale under a Rule 10b5-1 trading plan?

Yes. The disposition was effected by a broker under a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2025, consistent with issuer policy.

When was the Neurocrine Biosciences (NBIX) stock option originally granted and when would it have expired?

The non-qualified stock option was granted on May 20, 2016, vested in 12 equal monthly installments beginning June 20, 2016, and was scheduled to expire on May 20, 2026.